Q1 Earnings Forecast for NKTR Issued By HC Wainwright

Nektar Therapeutics (NASDAQ:NKTR) – Research analysts at HC Wainwright issued their Q1 2026 earnings per share estimates for shares of Nektar Therapeutics in a research note issued to investors on Tuesday, June 24th. HC Wainwright analyst A. He forecasts that the biopharmaceutical company will post earnings of ($3.00) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $120.00 target price on the stock. The consensus estimate for Nektar Therapeutics’ current full-year earnings is ($0.72) per share. HC Wainwright also issued estimates for Nektar Therapeutics’ Q3 2026 earnings at ($3.06) EPS.

Other analysts have also recently issued reports about the company. William Blair reissued a “market perform” rating on shares of Nektar Therapeutics in a research note on Monday, May 12th. Jefferies Financial Group raised Nektar Therapeutics from a “hold” rating to a “buy” rating and raised their target price for the stock from $15.00 to $30.00 in a research note on Friday, April 11th. BTIG Research lifted their price objective on Nektar Therapeutics from $60.00 to $100.00 and gave the company a “buy” rating in a research report on Tuesday. Oppenheimer raised Nektar Therapeutics from a “market perform” rating to an “outperform” rating and set a $90.00 price objective on the stock in a research report on Friday, March 14th. Finally, Wall Street Zen cut Nektar Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, May 14th. One analyst has rated the stock with a sell rating, one has assigned a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $76.43.

Nektar Therapeutics Trading Up 1.9%

NASDAQ NKTR opened at $29.68 on Thursday. The firm has a market cap of $368.33 million, a PE ratio of -3.09 and a beta of 0.55. Nektar Therapeutics has a 1-year low of $6.48 and a 1-year high of $37.38. The stock has a 50-day moving average of $11.19 and a 200-day moving average of $12.15.

Nektar Therapeutics (NASDAQ:NKTR) last released its earnings results on Thursday, May 8th. The biopharmaceutical company reported ($3.30) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.70) by ($0.60). Nektar Therapeutics had a negative net margin of 152.49% and a negative return on equity of 329.54%. The company had revenue of $10.46 million during the quarter, compared to the consensus estimate of $15.61 million. During the same period last year, the firm posted ($2.70) EPS.

Institutional Trading of Nektar Therapeutics

A number of hedge funds have recently made changes to their positions in NKTR. Connor Clark & Lunn Investment Management Ltd. boosted its position in shares of Nektar Therapeutics by 12.3% in the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 730,875 shares of the biopharmaceutical company’s stock worth $680,000 after purchasing an additional 80,034 shares in the last quarter. Monaco Asset Management SAM boosted its position in shares of Nektar Therapeutics by 1.8% in the 4th quarter. Monaco Asset Management SAM now owns 2,032,868 shares of the biopharmaceutical company’s stock worth $1,891,000 after purchasing an additional 35,648 shares in the last quarter. Sei Investments Co. boosted its position in shares of Nektar Therapeutics by 50.6% in the 4th quarter. Sei Investments Co. now owns 94,152 shares of the biopharmaceutical company’s stock worth $88,000 after purchasing an additional 31,654 shares in the last quarter. JPMorgan Chase & Co. boosted its position in shares of Nektar Therapeutics by 29.5% in the 4th quarter. JPMorgan Chase & Co. now owns 1,182,995 shares of the biopharmaceutical company’s stock worth $1,100,000 after purchasing an additional 269,695 shares in the last quarter. Finally, Wellington Management Group LLP boosted its position in shares of Nektar Therapeutics by 10.4% in the 4th quarter. Wellington Management Group LLP now owns 522,409 shares of the biopharmaceutical company’s stock worth $486,000 after purchasing an additional 49,319 shares in the last quarter. 75.88% of the stock is owned by institutional investors.

Nektar Therapeutics Company Profile

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.